A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 27 Aug 2015
At a glance
- Drugs PF 4856884 (Primary) ; Sunitinib
- Indications Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 21 Aug 2015 Status changed from completed to discontinued as per ClinicalTrials.gov record.
- 04 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.